Streetbeat News

Analyst Ratings

CFLT

Confluent (NASDAQ:CFLT) has received diverse analyst ratings over the last three months, with 17 analysts offering evaluations ranging from bullish to bearish. The average 12-month price target for CFLT has been raised to $32.41, up 19.68% from the previous $27.08, indicating a positive outlook from analysts. Recent actions include upgrades and maintenance of buy and outperform ratings, with price targets adjusted accordingly. Despite this, Confluent's financial performance shows challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management, suggesting potential hurdles ahead.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 12:00 pm

NEO

NeoGenomics (NASDAQ:NEO) received mixed ratings from 4 analysts, with an average 12-month price target of $21.25, reflecting a 6.26% decline from the previous target. The company, specializing in cancer-focused genetic testing, shows a revenue growth of 17.99% but struggles with profitability, having a net margin of -12.19% and ROE of -1.95%. Despite these challenges, its debt-to-equity ratio of 0.64 indicates a sound financial structure.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 12:00 pm

CSGP

CoStar Group (NASDAQ:CSGP) received mixed analyst ratings over the last quarter, with a shift towards more bullish views in the last 30 days. The average 12-month price target for CSGP has risen to $93.4, up 8.19% from the previous $86.33. Analyst actions include adjustments to ratings and price targets by firms such as Needham, JMP Securities, Goldman Sachs, and BMO Capital. CoStar Group, a leader in commercial real estate data, has shown strong financial performance with significant revenue growth, high net margin, and excellent ROE and ROA, positioning it above industry averages.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 12:00 pm

CSGP

Needham analyst Mayank Tandon maintains a Buy rating on CoStar Group (NASDAQ:CSGP) but lowers the price target from $105 to $90.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:50 am

RNG

Needham analyst Ryan Koontz maintains a Buy rating on RingCentral (NYSE:RNG) but lowers the price target from $46 to $42.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:48 am

DBVT

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on DBV Technologies (NASDAQ:DBVT) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:47 am

HALO

HC Wainwright & Co. analyst Mitchell Kapoor has maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and increased the price target from $48 to $50.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:45 am

RPTX

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Repare Therapeutics (NASDAQ:RPTX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:44 am

RAPT

HC Wainwright & Co. analyst Raghuram Selvaraju downgraded RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:42 am

SNOW

Needham analyst Mike Cikos has maintained a Buy rating on Snowflake (NYSE:SNOW) and increased the price target from $225 to $265.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:39 am